Kite releases pivotal CAR T therapy Phase III study results
Yescarta® is the first treatment in over 30 years to show statistically significant improvement in overall survival in R/R large B-cell lymphoma versus historical SOC.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
